Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

Artificial intelligence (AI) is not only boosting the business for tech companies. Healthcare and biotech industries are also ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.